GLP-1 & compounded medication availability in New Hampshire (2026)
New Hampshire handles out-of-state pharmacies with Yankee directness: there is a permit, a form (the board calls it MO-1), a fee, and a requirement to join the state’s prescription-monitoring program, clear enough that a pharmacy either qualifies or it doesn’t. Telemedicine has its own section of the state code, and it welcomes remote care at the in-person standard. Here is the full ten-line availability rundown for New Hampshire addresses.
The full ten-line rundown for New Hampshire
| Product line | Available in New Hampshire? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Filled by partner pharmacies holding New Hampshire’s nonresident permit. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | One flat national price at every dose, Nashua to the North Country. |
| NAD+ | Yes | 8–10 business days | Same online evaluation flow as the weight-loss lines. |
| Sermorelin | Yes | 8–10 business days | Dispensed by licensed partner pharmacies into every NH ZIP. |
| Glutathione | No | N/A | Not something we compound today; the row stays so the gap shows. |
| BPC-157 | Yes | 8–10 business days | Patient-specific compounded injectable; its federal section is below. |
| TB-500 | Yes | 8–10 business days | Patient-specific compounded injectable; see the federal facts below. |
| KPV | No | N/A | Not carried in any state, because our peptide formulary is injectable-only and KPV is not an injectable line. |
| Epitalon | Yes | 8–10 business days | Patient-specific compounded injectable; federal record below. |
| MOTS-c | Yes | 8–10 business days | Patient-specific compounded injectable with a federal record all its own, below. |
The No rows are the point. A catalog that hides its gaps is not a catalog worth reading. New Hampshire facts last reviewed November 16, 2026.
Research peptides in New Hampshire: BPC-157, TB-500, KPV, Epitalon & MOTS-c
OrderlyMeds ships four of these five lines to New Hampshire: BPC-157, TB-500, Epitalon and MOTS-c, compounded as injectables and dispensed on patient-specific prescriptions. KPV is the permanent absence, because it is not an injectable line and injectables are the only peptide form we compound. New Hampshire’s regulators have published nothing peptide-specific, so the record that matters is federal, and each line’s own federal facts are set out below regardless of what the availability column says.
BPC-157 in New Hampshire
Ships to New Hampshire as a compounded injectable, dispensed on a patient-specific prescription by a permitted pharmacy. Its federal record follows.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in New Hampshire
Part of the New Hampshire offering as a compounded injectable, patient-specific prescription required. Federal facts directly below.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in New Hampshire
Not compounded for New Hampshire or any other state. Ours is an injectable-only formulary and KPV sits outside it.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in New Hampshire
Available to New Hampshire patients as a compounded injectable under a patient-specific prescription. Read its federal section next.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in New Hampshire
Orderable for New Hampshire addresses as a compounded injectable on a patient-specific prescription, with a federal record below that is deliberately distinct from the four above.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What New Hampshire’s pharmacy regulators say about compounded medications
New Hampshire’s pharmacy oversight sits inside the Office of Professional Licensure and Certification, and its paperwork tells the story: an out-of-state pharmacy fills out a dedicated permit application, proves its home-state standing, and signs up for the prescription-monitoring program before the first package crosses into the state. The telemedicine side is equally settled, with its own section of the medical-practice code.
Out-of-state (non-resident/mail-order) pharmacies shipping prescription drugs to New Hampshire patients must register with the New Hampshire Board of Pharmacy and hold its permit — applied for on the board’s dedicated Non-Resident/Mail-Order Pharmacy form (MO-1) under administrative rule Ph 904 — and must register with the state’s Prescription Drug Monitoring Program under RSA 318-B:33. Sources: NH Board of Pharmacy — Non-Resident/Mail-Order Pharmacy permit application (MO-1) · NH Board of Pharmacy (OPLC).
RSA 329:1-d defines telemedicine as care delivered by electronic audio-visual means and permits diagnosis, treatment and prescribing via telemedicine at the same standard of care as in-person practice, with medical-record and follow-up requirements. Source: RSA 329:1-d.
No GLP-1-specific or peptide-specific restriction has been published by New Hampshire’s pharmacy regulators; compounded medications enter the state through the permit framework above. Source: New Hampshire Board of Pharmacy (OPLC).
A New Hampshire order runs the standard route: eligibility check online, an evaluation with a provider authorized for the state under RSA 329:1-d, then fulfillment by a pharmacy holding the nonresident permit, tracked to your door inside the published window. The price is the national price, and the state with no sales tax gets no markup from us either.
New Hampshire availability FAQs
Is compounded semaglutide available in New Hampshire?
Yes. OrderlyMeds ships compounded semaglutide to New Hampshire addresses from pharmacies holding the state’s nonresident permit, at the same flat national price.
Does New Hampshire recognize telemedicine prescriptions?
Yes. Telemedicine has its own section of state law (RSA 329:1-d), and prescribing through it is standard practice held to the in-person standard of care. The cited detail is in the regulator section above.
Can I get TB-500 or Epitalon shipped to New Hampshire?
Yes to both, as compounded injectables on patient-specific prescriptions, and BPC-157 and MOTS-c as well. KPV is the one we compound nowhere. Each section above carries that line’s cited federal record.
What's the delivery time to New Hampshire?
8–10 business days from signup is the published window, with tracking emailed when the pharmacy ships.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
